Another rare cannabis compound is offering a big profit opportunity…
That’s why, when InMed Pharmaceuticals Inc. (OTC: IMLFF) announced that it was using CBN as an active pharmaceutical ingredient (API) in two product candidates under development, we weren’t surprised.
As a quick refresher, CBN is a rare cannabinoid that is only found in trace amounts in the cannabis plant. Scientists are still studying its healing properties, but early results look promising.
“We are proud to be the first company to investigate cannabinol’s therapeutic potential in human clinical trials. InMed has completed more than 30 preclinical pharmacology and toxicology studies, identifying potential therapeutic advantages of CBN in specific disease models over the more common cannabinoids THC and CBD, as well as other rare variants,” InMed CEO Eric Adams said in a statement.
One of its products – INM-755 – is being developed to treat a rare genetic skin disease.
Its other product – INM-088 – could potentially treat ocular disease.
This is great news for the expansion of cannabis-based medicine.
The Future of Cannabis-Based Medicine
The Tufts Center for the Study of Drug Development estimated that it costs drugmakers $2.6 billion to develop a new prescription medicine that gains marketing approval.
Clinical trials alone can take six to seven years, which means it’s a very lengthy and expensive process to get a drug to market.
But InMed has an advantage thanks to its biosynthesis and bioinformatics technologies.
“We are simultaneously exploring innovative biosynthetic manufacturing methods and therapeutic applications of CBN formulations to target diseases with high unmet medical need,” InMed’s CEO said.
And that biosynthetic manufacturing comment is important.
It’s something Executive Director Don Yocham recently wrote about.
“In my view, looking 10 years down the road, most cannabinoids will be sourced through biosynthesis. It’s the only way to produce trace cannabinoids economically, and it’s the cheapest way to produce THC and CBD isolates essential for high-quality cannabis-infused edibles.”
So, as we see the rise of cannabis compounds being utilized in medicine, there will also be a massive need for biosynthesis.
It goes hand-in-hand with uncovering the full potential of the cannabis plant.
For InMed, it could provide contract manufacturing for other pharmaceutical companies as they further develop the ability to create specific cannabinoids.
To be clear, though, this is not a recommendation of InMed.
Rather, we wanted to illustrate the important role biosynthesis is playing because there will be other, better companies capitalizing on the wealth creation from mass-producing rare cannabis compounds.
Discover the companies using biosynthesis that have already made their way into our database, see how they rank, and unlock hundreds of other potential winners today with the “Marijuana Millionaire’s Vault.”
P.S. You can learn all about the proprietary rating system we use to rank the hundreds of cannabis companies contained in the “Vault” – otherwise known as NICILytics – in our free primer, “NICILytics Ratings Explained.”
4 responses to “Creation of Cannabis Compounds Offers Road to Massive Profits”
January 28 2020